Trial intelligence / Profile preview

CIK Cells and RFA in Cervical Cancer

NCT02490748Phase 2Active, not recruiting

Sponsor
Changzhou First People's Hospital
Start
Jul 2015
Primary completion
Jun 2038
Modality
Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01

Overview

A Phase 2 trial of unmodified CIK in Cervical Cancer (CC), sponsored by Changzhou First People's Hospital. Started Jul 2015; status: active, not recruiting.

02

Drugs

unmodified CIK
03

Conditions

Cervical Cancer (CC)

Beyond the preview

Go deeper on NCT02490748.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02490748.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call